PETRI DISH PERSPECTIVES

Manead Khin
  • 0,0 (0)
  • БИОНАУКИ

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

  1. -1 ДН.

    Episode 42: Otsuka

    Send a text In this episode of Petri Dish Perspectives, we explore the fascinating evolution of Otsuka Holdings, a company that defies traditional pharmaceutical stereotypes. From its origins in Japan as a chemical and nutrition-focused business to becoming a global biopharma innovator, Otsuka has built its reputation by targeting complex and often misunderstood disease areas such as psychiatric disorders, kidney disease, and digital medicine. We unpack the scientific and business journey behind blockbuster therapies like Abilify, examine how Otsuka balanced pharmaceuticals with nutrition and consumer health, and dive into the company’s unique culture of long-term thinking and unconventional innovation. We also explore how Otsuka expanded globally, navigated patent cliffs, embraced partnerships, and positioned itself for the future through digital therapeutics and precision medicine. If you’re interested in how companies succeed by thinking differently and what Otsuka teaches us about patience, diversification, and patient-centered innovation; this is an episode you won’t want to miss. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Pharma #Otsuka #DrugDevelopment #HealthcareInnovation #Biopharma #LifeSciences #PharmaceuticalIndustry #MentalHealthInnovation #DigitalTherapeutics #GlobalPharma #PrecisionMedicine #PetriDishPerspectives #BiotechPodcast Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    23 мин.

  2. 5 ФЕВР.

    Episode 41: Gene Therapies

    Send us a text What if medicine could fix disease at its source… by rewriting the genetic code itself? In this episode of Petri Dish Perspectives, we dive into the incredible story of gene therapy, one of the most ambitious and transformative frontiers in modern medicine. From early scientific discoveries about DNA and viral delivery systems, to heartbreaking clinical setbacks that nearly shut the field down, and finally to today’s life-changing treatments for rare diseases, cancer, and genetic disorders, gene therapy represents decades of persistence, innovation, and scientific courage. We explore the researchers who refused to give up, the breakthroughs that revived the field, and the biotech companies leading today’s gene therapy revolution, including pioneers developing CRISPR editing, viral vector platforms, and personalized cellular therapies. We also break down why gene therapy is reshaping the pharmaceutical industry and what the future may hold for curing previously untreatable diseases. If you love biotech, cutting-edge science, and the stories behind medical breakthroughs, this is an episode you don’t want to miss. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #GeneTherapy #Biotech #Genetics #CRISPR #CellTherapy #RareDisease #CancerResearch #Biopharma #MedicalInnovation #PrecisionMedicine #SciencePodcast #LifeSciences #DrugDevelopment #FutureOfMedicine #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    26 мин.

  3. 1 ФЕВР.

    January 2026: Biotech & Pharma NEWS Roundup

    Send us a text Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026! This month was dominated by a surge in Eli Lilly's deals, partnerships, etc.  🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    11 мин.

  4. 29 ЯНВ.

    Episode 40: Eisai

    Send us a text What does it take to spend decades chasing one of medicine’s hardest problems while the rest of the industry walks away? In this episode, we explore the remarkable story of Eisai, the Japanese pharmaceutical company that built its global identity around Alzheimer’s disease. From its founding during World War II and early commitment to ethical medicine, to the blockbuster success of Aricept, and finally the long, controversial road to Leqembi, Eisai’s journey is one of persistence, philosophy, and scientific conviction. We break down how Eisai partnered with Biogen, why leadership under Haruo Naito stayed the course when others exited neuroscience, and how a Japan-based company became a global force in CNS drug development. Along the way, we examine Eisai’s approach to risk, regulation, M&A, and what its future looks like beyond Alzheimer’s. This is a story about long-term thinking in a short-term industry and what happens when belief outlasts doubt. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin  #Eisai #Biotech #Pharma #Alzheimers #Neuroscience #DrugDevelopment #Biogen #HealthcareInnovation #PharmaHistory #LifeSciences #BiotechPodcast #ScienceAndBusiness #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    23 мин.

  5. 22 ЯНВ.

    Episode 39: Flagship Pioneering

    Send us a text Flagship Pioneering doesn’t wait for scientific breakthroughs. It builds them. In this episode, we dive deep into the origin story of one of the most influential venture creation firms in biotech and the mind behind it, Noubar Afeyan. From his early life shaped by uncertainty to the founding of a firm that treats biology like an engineering discipline, we explore how Flagship redefined what it means to create companies from first principles. We unpack how Flagship pioneered the venture creation model, its early proximity to the MIT and Harvard ecosystem, and how relationships with the Langer lab helped give rise to Moderna long before mRNA was mainstream. We also examine how Flagship systematically identified entire sectors, from AI-driven protein design to microbiome therapeutics and sustainable agriculture, and why its biggest bets often looked unreasonable for years before paying off. Finally, we look at the people who made their mark, the lessons Flagship teaches about patience and risk in biotech, and what’s next as the firm pushes into AI-native biology and programmable medicine. If you want to understand how the future of life sciences is designed, not discovered, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #FlagshipPioneering #Biotech #VentureCreation #Moderna #NoubarAfeyan #LifeSciences #Biotechnology #StartupStories #DeepTech #HealthcareInnovation #BioEngineering #AIinBiotech #ScienceToScale Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    23 мин.

  6. 15 ЯНВ.

    Episode 38: Biogen

    Send us a text Biogen is one of the most influential and controversial companies in modern biotechnology. Founded in the late 1970s by Nobel-level scientists who believed recombinant DNA would redefine medicine, Biogen helped turn neurology into a commercial field long before most pharma companies dared to enter it. In this episode, we trace Biogen’s full journey, from its academic origins and the rise of interferon therapies for multiple sclerosis, to blockbuster drugs like Avonex and Tysabri. We explore the diseases Biogen chose to fight, why the company doubled down on neurology, and how its scientific culture shaped both its breakthroughs and its blind spots. We then examine Biogen’s high-stakes pivot into Alzheimer’s disease, the controversy surrounding Aduhelm, and the cautious redemption attempt with Leqembi. Along the way, we highlight the people who built Biogen, the alumni who went on to shape the biotech industry, and the hard lessons learned when science, regulation, and patient hope collide. This is a story about ambition, uncertainty, and what it really takes to develop medicines when the biology refuses to cooperate. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biogen #Biotech #Pharma #Neuroscience #Alzheimers #MultipleSclerosis #DrugDevelopment #LifeSciences #Biopharma #HealthcareInnovation #SciencePodcast #BusinessOfBiotech #MedicalResearch #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    24 мин.

  7. 8 ЯНВ.

    Episode 37: Theranos

    Send us a text Theranos promised to revolutionize healthcare with a single drop of blood and became one of the most infamous failures in biotech history.  In this episode, we trace the full rise and fall of Elizabeth Holmes and Theranos, from its founding in 2003 to its dramatic collapse and criminal convictions nearly two decades later. We explore how ambition, secrecy, and Silicon Valley mythology allowed unproven science to scale into a $9 billion company, how powerful board members and investors failed to ask the right questions, and how whistleblowers and investigative journalism ultimately exposed the truth. This is a story about innovation without evidence, the dangers of charisma over data, and why medicine is uniquely unforgiving of hype. A cautionary tale at the intersection of biotech, venture capital, media, and power. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Theranos #ElizabethHolmes #Biotech #HealthcareInnovation #SiliconValley #MedicalFraud #InvestigativeJournalism #WallStreetJournal #JohnCarreyrou #VentureCapital #HealthTech #ScienceVsHype #BusinessPodcast #BiotechPodcast #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    26 мин.

  8. 1 ЯНВ.

    Episode 36: Novo Nordisk

    Send us a text Novo Nordisk’s rise is one of the most extraordinary stories in modern medicine. What began in 1920s Denmark as a response to a fatal disease evolved into a company that reshaped how the world treats diabetes, obesity, and metabolic illness. In this episode, we trace Novo Nordisk’s journey from the discovery of insulin and a decades-long rivalry between two Danish labs, to a landmark merger, global expansion, and steady leadership in diabetes care. We explore how the company mastered insulin manufacturing, pioneered drug delivery systems, and quietly built one of the most disciplined scientific cultures in pharma. This is a story about patience, focus, and how decades of unglamorous excellence can suddenly change the world. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #NovoNordisk #Biotech #Pharma #GLP1 #Ozempic #Wegovy #Diabetes #Obesity #Healthcare #LifeSciences #Biopharma #SciencePodcast #BusinessOfBiotech #MedicalInnovation #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

    24 мин.
См. все (45)

Об этом подкасте

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

Информация

  • Автор
    Manead Khin
  • Годы выхода
    2025 - 2026
  • Выпуски
    45
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © 2026 PETRI DISH PERSPECTIVES
  • Сайт подкаста
    PETRI DISH PERSPECTIVES